|
1
|
Wu DP: Leukemia. Internal Medicine.
9:600–616. 2009.In Chinese.
|
|
2
|
Chu JX, Yang CL and Yang TY: Leukemia
epidemiology report of China. Tianjing Med J. 6:323–326. 1982.In
Chinese.
|
|
3
|
Wang Y, Xu LH, Duan ZH, Cao KY, Luo JG, Xu
Y and Shi PJ: Effects of ADM on cell apoptosis and expression of
FAK mRNA in K562. J Trop Med. 12:1195–1198. 2012.In Chinese.
|
|
4
|
Moldovan GL and D’Andrea AD: How the
fanconi anemia pathway guards the genome. Annu Rev Genet.
43:223–249. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kim H and D’Andrea AD: Regulation of DNA
cross-link repair by the Fanconi anemia/BRCA pathway. Genes Dev.
26:1393–1408. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Romick-Rosendale LE, Lui VW, Grandis JR
and Wells SI: The Fanconi anemia pathway: repairing the link
between DNA damage and squamous cell carcinoma. Mutat Res.
743–744:78–88. 2013. View Article : Google Scholar
|
|
7
|
Chen Q, Van der Sluis PC, Boulware D,
Hazlehurst LA and Dalton WS: The FA/BRCA pathway is involved in
melphalan-induced DNA interstrand cross-link repair and accounts
for melphalan resistance in multiple myeloma cells. Blood.
106:698–705. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xiao H, Xiao Q, Zhang K, Zuo X and
Shrestha UK: Reversal of multidrug resistance by curcumin through
FA/BRCA pathway in multiple myeloma cell line MOLP-2/R. Ann
Hematol. 89:399–404. 2010. View Article : Google Scholar
|
|
9
|
Chen CC, Taniguchi T and D’Andrea A: The
Fanconi anemia (FA) pathway confers glioma resistance to DNA
alkylating agents. J Mol Med (Berl). 85:497–509. 2007. View Article : Google Scholar
|
|
10
|
Taniguchi T, Tischkowitz M, Ameziane N, et
al: Disruption of the Fanconi anemia-BRCA pathway in
cisplatin-sensitive ovarian tumors. Nat Med. 9:568–574. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
D’Andrea AD: Targeting DNA repair pathways
in AML. Best Pract Res Clin Haematol. 23:469–473. 2010. View Article : Google Scholar
|
|
12
|
Leveille F, Blom E, Medhurst AL, et al:
The Fanconi anemia gene product FANCF is a flexible adaptor
protein. J Biol Chem. 279:39421–39430. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
de Winter JP, van der Weel L, de Groot J,
et al: The Fanconi anemia protein FANCF forms a nuclear complex
with FANCA, FANCC and FANCG. Hum Mol Genet. 9:2665–2674. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang X and Li DH: Adriamycin-induced
apoptosis of tumor cells research progress. China Practical Med.
07:247–249. 2010.
|
|
15
|
Yarde DN, Oliveira V, Mathews L, et al:
Targeting the Fanconi anemia/BRCA pathway circumvents drug
resistance in multiple myeloma. Cancer Res. 69:9367–9375. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lundholm L, Haag P, Zong D, et al:
Resistance to DNA-damaging treatment in non-small cell lung cancer
tumor-initiating cells involves reduced DNA-PK/ATM activation and
diminished cell cycle arrest. Cell Death Dis. 4:e4782013.
View Article : Google Scholar : PubMed/NCBI
|
